Antitumor agents 279. Structure-activity relationship and in vivo studies of novel 2-(furan-2-yl)naphthalen-1-ol (FNO) analogs as potent and selective anti-breast cancer agents

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 52-57

  Dong, Yizhou ^a   Nakagawa Goto, Kyoko ^a   Lai, Chin Yu ^a   Kim, Yoon ^b,c   Morris Natschke, Susan L ^a   Lee, Eva Y H P ^b,c   Bastow, Kenneth F ^a   Lee, Kuo Hsiung ^a,d  

^a University of North Carolina   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

2 (Furan 2 yl)naphthalen 1 ol analogs; Anti breast tumor agents; Structure activity relationships

Indexed keywords

2 (FURAN 2 YL)NAPHTHALEN 1 OL ANALOG DERIVATIVE; ANTINEOPLASTIC AGENT; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FURANS; MICE; NAPHTHALENES; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 78650520583     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.077     Document Type: Article

References (17)

1. X. Wang, K.F. Bastow, C.M. Sun, Y.L. Lin, H.J. Yu, M.J. Don, T.S. Wu, S. Nakamura, and K.H. Lee J. Med. Chem. 47 2004 5816
2. X. Wang, K. Nakagawa-Goto, K.F. Bastow, M.J. Don, Y.L. Lin, T.S. Wu, and K.H. Lee J. Med. Chem. 49 2006 5631
3. Y. Dong, Q. Shi, H.C. Pai, C.Y. Peng, S.L. Pan, C.M. Teng, K. Nakagawa-Goto, D. Yu, Y.N. Liu, P.C. Wu, K.F. Bastow, S.L. Morris-Natschke, A. Brossi, J.Y. Lang, J.L. Hsu, M.C. Hung, E.Y. Lee, and K.H. Lee J. Med. Chem. 53 2010 2299
4. Y. Dong, Q. Shi, Y.-N. Liu, X. Wang, K.F. Bastow, and K.-H. Lee J. Med. Chem. 52 2009 3586
5. Y. Dong, Q. Shi, K. Nakagawa-Goto, P.C. Wu, K.F. Bastow, S.L. Morris-Natschke, and K.H. Lee Bioorg. Med. Chem. Lett. 19 2009 6289
6. 3, ppm): δ 8.09 (d, 1H, J = 8.4 Hz, Ar-H), 7.90 (d, 1H, J = 9.0 Hz, Ar-H), 7.55 (d, 1H, J = 8.7 Hz, Ar-H), 7.49 (dd, 1H, J = 7.2, 8.1 Hz, Ar-H), 7.40 (d, 1H, J = 6.3 Hz, Ar-H), 7.37 (d, 1H, J = 1.2 Hz, OCH)
7. Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L.M. Bennett, W. Ding, R. Bell, J. Rosentha, C. Hussey, T. Tran, M. McClure, C. Frye, T. Hattier, R. Phelps, A. Haugne-Strano, H. Katcher, K. Yakumo, Z. Gholami, D. Shaffer, S. Stone, S. Bayer, C. Wray, R. Bogden, P. Dayananth, J. Ward, P. Tonin, S. Narod, P.K. Bristow, F.H. Norris, L. Helvering, P. Morrison, P. Rosteck, M. Lai, J.C. Barrett, C. Lewis, S. Neuhausen, L. Cannon-Albright, D. Goldgar, R. Wiseman, A. Kamb, and J.H. Skolnick Science 266 1994 66
8. M.E. Moynahan Oncogene 21 2002 8994
9. N. Turner, A. Tutt, and A. Ashworth Nat. Rev. Cancer 4 2004 814
10. N.S. Ting, and W.H. Lee DNA Repair 3 2004 935
11. A.J. Poole, Y. Li, Y. Kim, S.-C.J. Lin, W.-H. Lee, and E.Y.H.P. Lee Science 314 2006 1467
12. 11,13 The mice were in a C57BL/6 and 129/Sv, mixed background. All animal experiments were in accordance with guidelines of federal and Institutional Animal Care and Use Committee at the University of California, Irvine. Treatment with 3: Three-month-old mice were treated with 0.1 mg of 3 or vehicle daily for 11 days. Stock solution of 3 was 10 mg/mL in dimethylsulfoxide. A mixture of 10 μL of stock solution, 30 μL of 40% polyethylene glycol, and 60 μL of 0.9% NaCl solution was prepared at the time of treatment. Vehicle includes all solution except 3. Vehicle or compound was administered ip every day for 11 days.
13. N. Shafee, C.R. Smith, S. Wei, Y. Kim, G.B. Mills, G.N. Hortobagyi, E.J. Stanbridge, and E.Y. Lee Cancer Res. 68 2008 3243
14. 2 were counted. For histological section, tissues were fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) at 4 °C overnight followed by paraffin embedding. Paraffin sections were stained with hematoxylin and eosin and examined by light microscopy. Immunostaining was performed following the protocol described in the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA.) To retrieve the antigen, slides were heated for 20 min in 10 mM citrate buffer, pH 6.0, in a microwave oven. BrdU monoclonal antibody (GeneTex, Inc., Irvine, CA) at 1:1000 dilution, and cyclin D1 polyclonal rat antibody (NeoMarkers/Thermo Fisher Scientific, Fremont, CA) at 1:500 dilution, respectively, were used for immunostaining.
15. H.L. LaMarca, and J.M. Rosen Endocrinology 149 2008 4317
16. E.Y.-H.P. Lee Curr. Opin. Obstet. Gynecol. 20 2008 68
17. E. Lim, F. Vaillant, D. Wu, N.C. Forrest, B. Pal, A.H. Hart, M.L. Asselin-Labat, D.E. Gyorki, T. Ward, A. Partanen, F. Feleppa, L.I. Huschtscha, H.J. Thorne, kConFab, S.B. Fox, M. Yan, J.D. French, M.A. Brown, G.K. Smyth, J.E. Visvader, and G.J. Lindeman Nat. Med. 15 2009 907